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Abstract
Background: Human rotavirus (HRoV) is the leading cause of severe gastroenteritis in infants and children under
the age of five years. No specific antiviral drug is available for HRoV infections and the treatment of viral diarrhea
is mainly based on rehydration and zinc treatment. In this study, we explored medicinal plants endemic to Turkey
flora as a source of anti-HRoV compunds.
Methods: We performed an antiviral screening on Ballota macrodonta, Salvia cryptantha and Rindera lanata extracts
by focus reduction assay. The extract with the highest selectivity index (SI) was selected; its antiviral activity was
further confirmed against other HRoV strains and by virus yield reduction assay. The step of viral replicative cycle
putatively inhibited was investigated by in vitro assays.
Results: The methanolic extract of R. lanata (Boraginaceae) showed the most favourable selectivity index. This
extract exhibited a dose-dependent inhibitory activity against three different HRoV strains (EC50 values ranging from
5.8 μg/ml to 25.5 μg/ml), but was inactive or barely active against other RNA viruses, namely human rhinovirus and
respiratory syncytial virus. The R. lanata extract targets the early steps of HRoV infection, likely by hampering virus
penetration into the cells.
Conclusion: These results make the R. lanata methanolic extract a promising starting material for a bioguided-
fractionation aimed at identifying anti-HRoV compounds. Further work is required to isolate the active principle and
assess its clinical potential.
Background
Gastroenteritis accounts for almost 20% of the deaths of
children under five years (National Collaborating Centre
for Women’s and Children’s Health. 2012). Viruses cause
approximately 70% of acute gastroenteritis, with rotavirus
infection frequently implicated in cases that require
hospitalization [1, 2]. Human rotavirus (HRoV, family
Reoviridae, genus Rotavirus) is responsible for 114 million
episodes of diarrhea, 25 million clinic visits, 2.4 million
hospital admissions, and more than 500,000 deaths in
children up to age 5 occur worldwide annually [3]. While
most of the episodes are mild, about 10% of cases lead to
dehydration requiring a doctor visit, and in resource-
constrained nations, one in 250 children will die from this
dehydration [4–7]. In Europe, HRoV infection accounts
for more than 50% of hospitalizations for gastroenteritis
and about one-third of emergency department visits [1, 4,
8]. At present, the treatment of viral diarrhea is based on
fluid replacement and zinc treatment in order to prevent
dehydration and to decrease the severity and duration. So
far, no specific antiviral drug is available to treat HRoV in-
fections. Discovering novel, safe and effective antiviral
molecules is a difficult task. One strategy is to explore
plants as a source of novel active compounds due to the
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large structural diversity of natural products. Indeed,
several studies reported on anti-HRoV activity by plant
extracts [9–14]. In this context, we performed an anti-
viral screening of three plants endemic to Turkey flora
and here we report on the anti-HRoV activity of
Rindera lanata (Boraginaceae). Boraginaceae is a plant
family represented by about 2,000 species in the world
[15]. The genus Rindera includes about 25 species
distributed mainly in Central and Western Asia [16],
four of which growing in Turkey, namely R. lanata, R.
caespiota, R. albida and R. dumani. Rindera species are
widely known as “Yünlü gelin” and used as an anti-
inflammatory agent in Anatolian folk medicine [17]. R.
lanata is used to alleviate joint pains in Iranian folk
medicine [18]. However, to the best of our knowledge,
R. lanata was neither traditionally used nor scientific-
ally investigated for antiviral properties. The present
study reports the anti-HRoV potency, the spectrum of
antiviral activity, and the probable mechanisms of anti-
viral action of the R. lanata methanol extract.
Methods
Chemicals
Quinic acid (>98%), malic acid (>99%), cholorogenic acid
(>95%), protocatechuic acid (>97%), caffeic acid (>98%),
p-coumaric acid (>98%), rosmarinic acid (>96%), rutin
(>94%), hesperidin (>97%) and hyperoside (>97%) were
purchased from Sigma-Aldrich (Germany). Apigenin
(>99%) and rhamnetin (>99%) were purchased from
Fluka (Germany).
Plant material and extraction
Taxonomic identification of the plant materials were
confirmed by the senior taxonomist Dr. Murad Aydin
Sanda, from the Department of Biology, Selcuk Univer-
sity. The voucher specimens were deposited at the
Konya Herbarium of Department of Biology, Selcuk
University, Konya-Turkey. Rindera lanata (Lam.)
Bunge var. lanata (Lam.) Bunge (family: Boraginaceae)
was collected from Balcilar-Taskent, Konya-Turkey,
May 2014, (Voucher No: GZ 1410). Salvia cryptantha
Montbret et Aucher ex Bentham (family: Lamiaceae)
was provided by Selcuk University, Aladdin Keykubat
Campus, Yukselen village- Campus road, Konya-Turkey,
June 2014, (Voucher No: GZ 1421). Ballota macrodonta
Boiss. et Bal (family: Lamiaceae): was collected from
Camardi, Mazmili Mountain, Nigde-Turkey, June 2014
(Voucher No: 1425).
The plant materials were dried at room temperature.
The air-dried aerial parts (leaves, stem, flowers) were
collected as a mix (10 g) and were macerated with
250 mL of methanol at room temperature for 24 h.
Methanol was then removed with a rotary evaporator at
40 °C. The extracts were stored at +4 °C until analyzed.
Yield of these extracts were 17.83%, 14.86% and 4.90%,
respectively.
For both cell viability assays and infectivity assays, the
extracts were reconstituted in sterile methanol, to a
concentration of 25 mg/ml. Every experiment was
performed with freshly resuspended extracts.
LC-MS/MS analysis
LC-MS/MS analyses of the phenolic compounds were
performed on a Shimadzu Nexera UHPLC system
coupled to a triple quadrupole LC-MS8040 system
equipped with an ESI source operating in both positive
and negative ionization modes. The liquid chromato-
graph was equipped with LC-30 AD binary pumps,
DGU-20A3R degasser, CTO-10ASvp column oven and
SIL-30 AC autosampler. The chromatographic separ-
ation was performed on a C18 reversed-phase Inertsil
ODS-4 (150 mm × 4.6 mm, 3 μm particle size, GL Sci-
ences, The Netherlands) analytical column. The column
was maintained at 40 °C. The elution gradient consisted
of mobile phase with eluent A (water, 5 mM ammo-
nium formate and 0.1% formic acid) and eluent B
(methanol, 5 mM ammonium formate and 0.1% formic
acid). The mobile phase gradient was as follows; from
40% to 90% eluent B in 20 min, then 90% B for 4 min.
The flow rate of the mobile phase was 0.5 mL/min and
the injection volume 4 μL.
MS conditions were: interface temperature; 350 °C, DL
temperature; 250 °C, heat block temperature; 400 °C,
nebulizing gas flow (Nitrogen); 3 L/min and drying gas
flow (Nitrogen); 15 L/min. LC-MS/MS data were collected
and processed by LabSolutions software (Shimadzu,
Kyoto, Japan). The multiple reaction monitoring (MRM)
mode was used to quantify the analytes by adopting two
or three transitions per compound, the first one for quan-
titative purposes and the second and/or the third one for
confirmation. These analytical conditions have been suc-
cessfully used to analyze other plant matrices [19–21].
Cell lines and viruses
African green monkey kidney epithelial cells (MA104)
and human epithelial adenocarcinoma HeLa cells
(ATCC® CCL-2) were propagated in Dulbecco’s Modi-
fied Eagle Medium (DMEM; Sigma, St. Louis, MO)
supplemented with 1% (v/v) Zell Shield (Minerva Bio-
labs, Berlin, Germany) and heat inactivated, 10% (v/v)
fetal bovine serum (Sigma). Human epithelial cells
HEp-2 (ATCC® CCL-23) were grown as monolayers in
Eagle’s minimal essential medium (MEM) (Gibco/BRL,
Gaithersburg, MD) supplemented with 10% FBS and
1% antibiotic-antimycotic solution. HRoV strains Wa
(ATCC® VR-2018), HRoV 408 (ATCC® VR-2273) and
DS-1 (ATCC® VR-2550) were purchased from ATCC;
virus was activated with 5 μg/ml of porcine pancreatic
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trypsin type IX (Sigma, St. Louis, Mo.) for 30 min at 37 °C
and propagated in MA104 cells by using DMEM contain-
ing 0.5 μg of trypsin per ml as described previously [22].
Respiratory Syncytial Virus (RSV) strain A2 (ATCC® VR-
1540) was propagated in HEp-2 and titrated by the indir-
ect immunoperoxidase staining procedure using an RSV
monoclonal antibody (Ab35958; Abcam, Cambridge,
United Kingdom) as described previously [23]. Human
rhinovirus (HRhV) 1A (ATCC® VR-1559) was cultured in
HeLa cells, at 34 °C, in a humidified 5% CO2 incubator.
When the full cytopathic effect (CPE) developed, cells and
supernatants were harvested, pooled, frozen and thawed
three times, clarified and stored at −70 °C. HRhV titers
were determined by the standard plaque method as de-
scribed previously [22].
Cell viability assay
Cells were seeded at a density of 5 × 103/well in 96-well
plates and treated the following day with serially-
diluted methanol extracts of B. macrodonta, S. cryptantha
or R. lanata (1.2 μg/ml to 1666 μg/ml) to generate dose–
response curves. Control wells (100% of viability) were
prepared by treating cells with equal volumes of methanol,
corresponding to 6.7% (v/v) to 0.0048% (v/v) in cell media.
After 24 h of incubation, cell viability was determined
using the CellTiter 96 Proliferation Assay Kit (Promega,
Madison, WI, USA), and following the manufacturer’s
instructions. Absorbances of both treated (AbsT) and
untreated (AbsMETH) samples were measured using a
Microplate Reader (Model 680, BIORAD) at 490 nm. The
% of cell viability was calculated according to the following
formula: (AbsT X 100)/AbsMETH. The 50% cytotoxic con-
centration (CC50) was determined using logarithmic
viability curves. Where possible, a selectivity index (SI)
was calculated by dividing the CC50 by the EC50 value.
Rotavirus inhibition assays
The anti-HRoV efficacy of methanol extracts of B. macro-
donta, S. cryptantha and R. lanata was determined by
focus reduction assay. Assays of inhibition of rotavirus in-
fectivity were carried out with confluent MA104 cell
monolayers plated in 96-well trays, as described elsewhere
[22]. Cells were treated for 2 h at 37 °C with methanol
extract of R. lanata, at concentrations ranging from 1.2 to
300 μg/ml in serum-free medium prior to virus addition.
HRoV infection was performed at a multiplicity of infec-
tion (MOI) of 0.02 for 1 h at 37 °C, in presence of the
methanol extract unless otherwise stated. Infected cells
were washed with serum-free medium, fresh methanol
extract was added, and cells were incubated in this
medium at 37 °C in a humidified incubator in 5% (vol/vol)
CO2–95% (vol/vol) air. For time of addition assays, serial
dilutions of extracts were added on cells alternatively 2 h
before infection or during infection or post infection.
Control samples were prepared by treating cells with
culture medium supplemented with equal volumes of
methanol and taken as 100% of infection. After 16 h of
incubation, infected cells were fixed with cold acetone-
methanol (50:50), and viral titers determined by indir-
ect immunostaining by using a mouse monoclonal
antibody directed to human rotavirus VP6 (0036;
Villeurbanne, France), and the secondary antibody
peroxidase-conjugated AffiniPure F(ab’)2 Fragment
Goat Anti-Mouse IgG (H + L) (Jackson ImmunoRe-
search Laboratories Inc., 872 W. Baltimore Pike, West
Grove, PA 19390). Blockade of viral infectivity is
expressed as mean % ± SD. Where possible, anti-viral
effective concentration (EC50) values were calculated
by regression analysis using the dose–response curves
generated from the experimental data, using PRISM 4
(GraphPad Software, San Diego, CA, U.S.A.).
RSV inhibition assay
HEp-2 cells were first seeded (at 8 × 103 cells/well) in 96
well plate. The methanol extract of R. lanata was serially
diluted in medium (from 300 to 0.4 μg/ml) and incubated
with cells for 2 h at 37 °C, then mixtures of extracts and
virus (MOI 0.01) were added to cells to allow the viral
adsorption for 3 h at 37 °C; the monolayers were then
washed and overlaid with 1.2% methylcellulose medium
containing serial dilutions of extract. Control wells (100%
of infection) were prepared by treating cells with equal
volumes of methanol. Three days post-infection, cells were
fixed with cold methanol and acetone (50:50) for 1 min
and subjected to RSV-specific immunostaining. Immuno-
stained plaques were counted, and the percent inhibition
of virus infectivity was determined by comparing the
number of plaques in treated wells with the number in
untreated control wells.
Rhinovirus inhibition assay
HeLa cells were first seeded (at 8 × 104 cells/well) in 24
well plates. 24 h later the methanol extract of R. lanata
was serially diluted in medium (from 300 μg/ml to 0.4 μg/
ml) and added to cell monolayers. After 2 h of incubation
(37 °C, 5% CO2), medium was removed and infection was
performed with 200 μL/well with HRhV 1A (MOI 0.0002)
and different concentrations of the extract. The infected
cells were incubated at 34 °C for 1 h, then washed with
medium, and overlaid with a 1:1 combination of 1.6%
SeaPlaque Agarose and 2X DMEM containing the extract.
Control wells (100% of infection) were prepared by treat-
ing cells with equal volumes of methanol. The plates were
incubated at 34 °C for 3 days. After incubation, the plates
were fixed with 7.5% formaldehyde (Fluka) and stained
with crystal violet (Sigma, St. Louis, Mo.). The number of
plaques formed was counted.
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Assay of rotavirus yield
To test the ability of R. lanata extract to inhibit multiple
cycles of HRoV replication, confluent MA104 cells in
24-well trays were infected with trypsin-activated Wa
rotavirus (MOI 0.02) for 1 h at 37 °C and washed as
above. Cells were incubated in medium supplemented
with 0.5 μg/ml porcine trypsin and 1.2, 3.6, 11, 33, 100,
300 μg/ml of R. lanata extract. Infected cells and cell su-
pernatants were harvested at 48 h post infection and
virus titers determined by indirect immunostaining of
MA104 cell monolayers inoculated with serial dilutions
of the samples. The assay was performed in triplicate.
One-way analysis of variance (ANOVA), followed by the
Bonferroni test, was used to assess the statistical signifi-
cance of differences in virus titers. Significance was set
at 95% level.
Virus inactivation assay
Trypsin-activated HRoV Wa was incubated for 2 h at
4 °C in presence of 100 μg/ml of R. lanata extract.
After this incubation, both treated and untreated viruses
were titrated. Viral yields were determined by indirect
immunostaning, by counting the number of infective
events at dilutions at which the extract was no more active
(i.e. 1:1024, 1:2048, 1:4096).
Entry assays
In order to test the effect of R. lanata methanol extract
on the rotavirus-cell penetration process, an entry assay
was performed. Briefly, MA104 cells were cultured to
confluence in 96-well trays; cells were washed twice
with DMEM and then cooled on ice for 20 min. Acti-
vated virus, which had been cooled to 4 °C, was allowed
to attach to cells on ice for 1 h at 4 °C, at a MOI of
0.02. Cells were washed three times, then R. lanata
methanol extract was added to the cells (at concentra-
tions ranging from 1.2 μg/ml to 300 μg/ml) and virus
particles were allowed to penetrate inside cells for 1 h
at 37 °C. The entry of the viral particles was stopped
with two quick washes with 3 mM EGTA in PBS, which
releases the outer layer of the virions and causes the
particles to detach from the cell surface [24, 25]; finally,
cells were incubated with warm DMEM. After 16 h,
cells were fixed and blockade of virus entry were deter-
mined by focus reduction assay as described above, and
expressed as mean percentages of untreated control ±
SEM. Significant differences were assessed by one way
ANOVA, using PRISM 4 (GraphPad Software, San
Diego, California, USA).
Rotavirus cell-binding assay
Confluent MA104 cell monolayers in 24-well trays were
washed, incubated with R. lanata methanol extract for
2 h at 37 °C and cooled on ice for 20 min in the con-
tinuing presence of the extract. Trypsin-activated virus,
Table 1 Antiviral activity of R. lanata, B. macrodonta and S.
cryptantha methanolic extract against HRoV Wa
HRoV strain Source EC50a (μg/ml) –
95% C.I.b
CC50c(μg/ml) SId
Wa Salvia cryptantha 16.3 (9.0–29.6) 134.8 8.3
Ballota macrodonta 8.1 (6.9–9.7) 445.5 55
Rindera lanata 5.8 (4.6–7.2) 1179 205
aEC50 half maximal effective concentration
bC.I. confidence interval
cCC50 half maximal cytotoxic concentration
dSI selectivity index
Table 2 Quantification of identified phenolic compounds in methanol extract of Rindera lanata by LC ESI MS/MS in negative
ionization mode
Analytes RT [M-H]−(m/z) MS2 (m/z) Equation Amounta
Quinic acid 3.36 190.95 85, 93 f(x) = 33.66x + 25133 2318.60 ± 111.29
Malic acid 3.60 133.05 115, 71 f(x) = 93.61x-5673 9381.66 ± 497.23
Chlorogenic acid 5.29 353 191 f(x) = 48.98x + 26780 23.63 ± 1.16
Protocatechuic acid 5.51 152.95 109, 108 f(x) = 36.86x + 6197 32.3 ± 1.65
Caffeic acid 7.11 178.95 135, 134, 89 f(x) = 1585x + 83958 13.53 ± 0.70
p-Coumaric acid 9.17 162.95 119, 93 f (x) = 73.53x + 27064 173.59 ± 8.85
Rosmarinic acid 9.19 358.9 161, 133 f (x) = 18.02x + 1149 706.38 ± 34.61
Rutin 9.67 609.1 300, 271, 301 f(x) = 51.88 + 3841 101.89 ± 5.09
Hesperidin 9.69 611.1 303, 465 f(x) = 1975.77 + 105641 399.74 ± 19.59
Hyperoside 9.96 463.1 300, 301 f(x) = 0.98x + 827 118.00 ± 5.78
Apigenin 16.73 268.95 151, 117 f(x) = 543.79 + 18525 0.10 ± 0.005
Rhamnetin 18.41 314.95 165, 121, 300 f(x) = 110.09 + 632.44 0.23 ± 0.014
RT: Retention time
[M-H]−: Deprotonated ions of the standard compounds
MS2: MRM fragments for the related molecular ions
aValues in μg/g (w/w) of plant methanol extract
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which had been cooled to 4 °C, was allowed to attach
to cells on ice for 1 h (MOI = 3) in presence of R.
lanata methanol extract. Cells were washed with cold
DMEM, followed by addition of cold DMEM. Cells
were subjected to two rounds of freeze-thawing, incu-
bated at 37 °C for 30 min with 10 μg/ml porcine trypsin
to release bound virus, and the lysate clarified by low
speed centrifugation for 10 min. Cell-bound virus titers
were determined by indirect immunostaining as above.
Significant differences were assessed by Student’s t-test,
using PRISM 4 (GraphPad Software, San Diego, Califor-
nia, USA).
Results
R. lanata methanolic extract is endowed with anti-HRoV
activity
In a first set of experiments, we tested the anti-HRoV
activity of R. lanata, B. macrodonta and S. cryptantha
methanolic extracts against HRoV Wa. Results depicted
in Table 1 show that all the methanolic extracts were
endowed with anti-HRoV activity, with EC50s ranging
from 5.8 to 16.3 μg/ml. To exclude the possibility that
the antiviral activity might depend on a cytotoxic effect,
cell viability assays were performed on uninfected cells,
challenged with the extracts under the same conditions
as the antiviral assays. Control wells were prepared by
treating cells with equal volumes of methanol, corre-
sponding to 6.7% (v/v) to 0.0048% (v/v) in cell media:
these low volumes of methanol were non cytotoxic and
did not influence viral replication (data not shown). As
shown in Table 1, R. lanata showed the most favourable
selectivity index (SI), i.e. 205. Therefore, we focused our
research on R. lanata methanolic extract. Firstly, we
performed LC-MS/MS analysis to identify and quantify
phenolic components that characterize R. lanata metha-
nolic extract, in order to make sure of the reproducibil-
ity of our study and to ensure that the results of future
studies will be comparable to the ones of this research.
The LC-MS/MS analysis allowed to identify and quantify
twelve phenolic compounds in R. lanata methanolic
extract and the results are listed in Table 2. Malic acid
(9381.66 μg/g extract) and quinic acid (2318.60 μg/g)
were found to be major phenolic component followed
by rosmarinic acid (706.38 μg/g) hesperidin (399.74 μg/g
extract), p-coumaric acid (173.59 μg/g extract), and
hyperoside (118.00 μg/g extract). In accordance with
these results, R. lanata belongs to the Boraginaceae fam-
ily, characterized by the presence of rosmarinic acid and
related components [26]
To assess the spectrum of anti-HRoV activity, the
extract was tested against two additional HRoV strains,
namely HRoV 408 and DS-1. The results reported in
Table 3 clearly show that the extract was effective in inhi-
biting the infectivity of both strains tested, although to a
different extent, with EC50 values of 25.5 μg/ml and
14.3 μg/ml respectively. The specificity of the anti-HRoV
activity was assessed by performing antiviral assays against
two unrelated viruses, namely the rhinovirus (HRhV) and
the respiratory syncytial virus (RSV). These were selected
for being both RNA viruses as HRoV and representative of
naked (HRhV) or enveloped (RSV) viruses. The methano-
lic extract of R. lanata did not show any antiviral activity
against HRhV (Table 4) while it was possible to calculate
an EC50 against RSV (45.3 μg/ml). However, the selectivity
index was very low (4), suggesting that the anti-RSV activ-
ity was mainly an expression of a cytotoxic effect (Table 4).
Taken together, the results presented so far demonstrate
Table 4 Antiviral activity of R. lanata methanolic extract against
HRhV 1A and RSV A2
Virus EC50
a (μg/ml) – 95% C.I.b CC50
c (μg/ml) SId
HRhV 1A n.a. 804.3 n.a.
RSV A2 45.28 (30.20–67.88) 183.9 4.1
aEC50 half maximal effective concentration
bC.I. confidence interval
cCC50 half maximal cytotoxic concentration
dSI selectivity index
n.a. not assessable
Table 3 Antiviral activity of R. lanata methanolic extract against
HRoV strains
HRoV strain EC50
a (μg/ml) – 95% C.I.b CC50c (μg/ml) SId
HRoV408 25.5 (15.6–41.6) 1179 46
DS-1 14.3 (6.7–30.2) 1179 83
aEC50 half maximal effective concentration
bC.I. confidence interval
cCC50 half maximal cytotoxic concentration
dSI selectivity index
Fig. 1 Effect of methanol extract of R. lanata on multiple cycles of
HRoV-Wa replication. Cells were treated after virus infection at the
given concentrations. The titer of HRoV in the treated samples is
expressed as focus-forming units per ml (FFU/ml). Error bars represent
the SD of the mean of 3 independent experiments. One-way analysis
of variance (ANOVA), followed by the Bonferroni test, was used to
assess the statistical significance of differences in virus titers.
Significance was set at the 95% level. *p < 0.05; ***p < 0.001
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that the R. lanata methanolic extract exerts a specific
anti-HRoV effect which is not strain restricted.
To investigate further the extract antiviral efficacy, a
virus yield reduction assay was performed by treating
cells after viral inoculum, and titrating viral progeny.
We chose this experimental setting because represents
a stringent kind of test, allowing multiple cycles of
replication to occur before measuring antiviral activity.
Figure 1 shows that the extract significantly (0.001 <
pANOVA < 0.05) reduced the titer of HRoV progeny in a
dose-dependent manner. This result confirms that R.
lanata methanolic extract affects HRoV replication,
likely by targeting a specific step of viral replication.
R. lanata methanolic extract inhibits viral infectivity by
targeting the early steps of viral infection
To investigate the step of viral replication inhibited by the
extract, we performed time of addition assays by treating
cells with serial dilutions of extract 2 h before infection or
during infection or post-infection. The results, depicted in
Fig. 2, show that the first two treatment protocols were ac-
tive while the latter was not, suggesting a probable activity
of the extract on the early steps of HRoV infection. To ex-
plore this hypothesis, more stringent tests were performed
to assess the putative target of the extract (i.e. the viral
particle or the virus-cell interactions). Firstly, we assessed
the extract ability to directly inactivate the virus particle
by incubating HRoV with a high concentration (100 μg/
ml) of methanolic extract and then measuring the viral
titer at dilutions corresponding at concentrations that are
not antiviral when added on cells. Results depicted in
Fig. 3a demonstrate that the methanolic extract did not
inactivate the virus particles. Having excluded the virus
particle as a target of the antiviral activity of the extract,
we explored the possibility that the interaction between
Fig. 2 Time-of-addition experiments were performed by treating
cells with R. lanata methanolic extract for 2 h before infection (B),
for 1 h during infection (C) or immediately after infection (D).
Control experiments were performed by treating cells both
before and during viral inoculum (A). The infectivity titers of virus
in the treated samples are expressed as a percentage of the titer
obtained in theuntreated control. Error bars represent the SD of
the mean of 3 independent experiments
Fig. 3 Investigation of the mechanism of anti-HRoV action of R. lanata methanol extract. Panel a shows the evaluation of the virucidal effect of R.
lanata methanol extract on infectious HRoV particles. On the y axis, the HRoV Wa infectious titers are expressed as focus-forming units per ml
(FFU/ml). Panel b displays the effect of R. lanata methanol extract on Wa binding to the MA104 cell surface; on the y axis, the infectious titer of
Wa bound to cells is expressed as a % of the titer bound to control MA104 cells in the absence of treatment. Panel c shows the effect of R. lanata
methanol extract on HRoV-Wa entry into MA104 cells; the viral titer measured in the treated samples is expressed as a % of the titer obtained in
the untreated control. On the three graphs, error bars represent the SD of the mean of 3 independent experiments.* p < 0.05
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the viral particles and the cell surface could be affected
by the extract. To this aim HRoV-cell binding assays
were performed. The results (Fig. 3b) demonstrate that
the treatment did not reduce significantly (p > 0.05) the
titer of virus particles bound to the surface of treated cells,
thus suggesting that inhibition occurs at a post-binding
stage. To verify this hypothesis, entry assays were per-
formed by treating cells during virus penetration. Figure 3c
shows that the R. lanata methanolic extract significantly
reduced HRoV infectivity in a dose-dependent manner
when added immediately after the virus-cell attachment
step (i.e. during cell penetration).
Discussion
Several recent studies demonstrate that plant extracts
are deeply explored for their antiviral potential against
HRoV [9–14, 27–29].
In this study we show that the methanolic extract of R.
lanata is endowed with anti-HRoV activity. Although
several molecules inside this crude extract can contrib-
ute to its effect, each one acting through a specific
mechanism, some preliminary conclusions can be drawn
on the main mechanism of antiviral action. The treat-
ment with the methanolic extract of R. lanata does not
alter the ability of HRoV to attach on the host cell sur-
face, as shown by the results of the binding experiments;
moreover, the results of the virus inactivation assays rule
out a direct antiviral effect of any component of R.
lanata methanolic extract. By contrast, the results sug-
gest that inhibition takes place at a post-attachment
stage, since no antiviral effect is shown when the metha-
nolic extract is added on cells 1 h after the viral inocu-
lum (Fig. 2) - i.e. when the entry process already started
and the 30% of the inoculated HRoV particles already
entered inside cells [30]. Nevertheless, since the inhib-
ition of entry is not complete it is likely that other, yet
unidentified mechanisms, contribute to the overall anti-
viral activity of the extract. Of note, cells pre-treatment
with the extract affects their susceptibility to the HRoV
infection (Fig. 2) suggesting that the extract may target
cellular functions required for virus replication. Among
the major phenolic compounds present in the methanol
extract of R. lanata hesperidin is known to a have anti-
HRoV activity [31] and might be responsible, at least in
part, to the anti-HRoV effect of the extract.
Conclusion
In conclusion, the favorable selectivity index and the
anti-HRoV activity against multiple viral strains make
the R.lanata extract a promising starting material for a
bioguided-fractionation aimed at identifying anti-HRoV
compounds. Further work remains to be done in order
to isolate the active principle, elucidate its mechanism of
action and assess its clinical potential.
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